OLMALINC and prostate cancer: We demonstrate that LINC00263 was overexpressed in several cancers, including lung adenocarcinoma, squamous cell carcinoma, colorectal cancer, renal cell carcinoma, hepatic carcinoma, breast cancer, and prostate cancer based on the analysis of gene expression data.